Direct, Definitive Genomics
Innovative solutions for the discovery, detection and quantification of genomic structural variations for clinical/preclinical gene and cell therapy providers.
Services
Follow a manual added link
Process Optimization
On/Off Target Effects
Quality Control
Delivery Monitoring
Products
KromaTiD News
Press Releases
& Company News
- KromaTiD Announces Launch of dGH SCREEN™
- KromaTiD Appoints Nathan Wood as Chief Executive Officer
- KromaTiD receives $2.0 million of growth capital investment from BroadOak Capital Partners
- Applied Spectral Imaging and KromaTiD announce strategic commercial partnership
- KromaTiD and dGH in-Site featured in Genetic Engineering & Biotechnology News
Videos, Presentations
& Webinars
- Dr. Chris Tompkins and Erin Cross present webinar for the launch of dGH SCREEN™ for unbiased whole genome analysis of chromosomal structural rearrangements
- Dr. Lauren Kinner-Bibeau presents webinar on single-cell measurements of genomic inserts and transgenes
- KromaTiD presents at the 2020 virtual NextGen Omics Series
- KromaTiD CTO Dr. Chris Tompkins presents at the 2020 Cell & Gene Therapy Virtual Congress
Market News
- Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
- A CRISPR gene-editing breakthrough stops life-threatening disease in Intellia-sponsored study
- WHO issues new recommendations on human genome editing for the advancement of public health
Essential, unique tools for discovery, detection and quantification of genomic structural variations